Continuous vancomycin infusion versus intermittent infusion for dose adjustment in patients with under therapeutic drug level

Continuous vancomycin infusion versus intermittent infusion in critically ill patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210122005

Enrollment

Registered

2021-01-22

Start date

2021-07-04

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

critically ill methicillin-resistant vancomycin level under therapeutic target vancomycin therapeutic drug monitoring continuous infusion

Interventions

Vancomycin is prepared in 0.9%NaCl solution with concentration of 10mg/ml Initial daily dose of vancomycin for continuous infusion (mg/day) is calculated by (17 x CrCl) + 100 Creatinine clearance (C

Experimental Drug

Continuous vancomycin infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adult patients (18 years old or over) 2. Creatinine clearance (CrCl) by Cockcroft-Gault formula of more than 30 ml/min/1.73m2 3. Had or was suspected of having Staphylococcal or Enterococcal infections 4. Vancomycin was indicated and was anticipated for at least 48 hours.

Exclusion criteria

Exclusion criteria: 1. History of receiving vancomycin within 48 hours before the study 2. History of vancomycin allergy 3. Pregnant or lactating woman 4. Patient with acute kidney injury 5. Body mass index below 15 kg/m2 5. Receiving renal replacement therapy or extracorporeal membrane oxygenator 6. The treating physician considers as inappropriate for continuous infusion. 7. Do-not-resuscitation and terminally ill condition 8. Denials the consent

Design outcomes

Primary

Measure	Time frame
Serum vancomycin level within the therapeutic target within 48 hours At 48 hours after continuous infusion Serum vancomycin level	—

Secondary

Measure	Time frame
Serum vancomycin level within the therapeutic target within 96 hours At 96 hours after continuous infusion Serum vancomycin level,Number of serum vancomycin level tested Before reaching the therapeutic target Number of serum vancomycin level tested,Successful treatment Within the admission Resolution of the infection,Mortality 14 days after continuous infusion and within the admission Mortality at 14 days after continuous infusion and in-hospital mortality,Acute kidney injury 48 hours after discontinuation of continuous vancomycin infusion Absolute increase in serum creatinine at least 0.3 mg/dL or at least 1.5-fold from baseline,Occurrence of adverse drug reaction 48 hours after discontinuation of continuous vancomycin infusion drug induced cytopenia, vancomycin related phlebitis, ototoxicity	—

Measure

Time frame

Serum vancomycin level within the therapeutic target within 96 hours At 96 hours after continuous infusion Serum vancomycin level,Number of serum vancomycin level tested Before reaching the therapeutic target Number of serum vancomycin level tested,Successful treatment Within the admission Resolution of the infection,Mortality 14 days after continuous infusion and within the admission Mortality at 14 days after continuous infusion and in-hospital mortality,Acute kidney injury 48 hours after discontinuation of continuous vancomycin infusion Absolute increase in serum creatinine at least 0.3 mg/dL or at least 1.5-fold from baseline,Occurrence of adverse drug reaction 48 hours after discontinuation of continuous vancomycin infusion drug induced cytopenia, vancomycin related phlebitis, ototoxicity

—

Countries

Thailand

Contacts

Public ContactChailat Maluangnon

Siriraj Hospital

chailat.mal@mahidol.ac.th0818307373

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026